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Abstract: Evidence suggests that patient-centred medical home (PCMH) is more effective than
standard general practitioner care in improving patient outcomes in primary care. This paper reports
on the design, early implementation experiences, and early findings of the 12-month PCMH model
called ‘WellNet’ delivered across six primary care practices in Sydney, Australia. The WellNet study
sample comprises 589 consented participants in the intervention group receiving enhanced primary
care in the form of patient-tailored chronic disease management plan, improved self-management
support, and regular monitoring by general practitioners (GPs) and trained clinical coordinators.
The comparison group consisted of 7750 patients who were matched based on age, gender, type and
number of chronic diseases who received standard GP care. Data collected include sociodemographic
characteristics, clinical measures, and self-reported health assessments at baseline and 12 months.
Early study findings show the mean age of the study participants was 70 years with nearly even
gender distribution of males (49.7%) and females (50.3%). The most prevalent chronic diseases
in descending order were circulatory system disorders (69.8%), diabetes (47.4%), musculoskeletal
disorders (43.5%), respiratory diseases (28.7%), mental illness (18.8%), and cancer (13.6%). To our
knowledge, the WellNet study is the first study in Australia to generate evidence on the feasibility of
design, recruitment, and implementation of a comprehensive PCMH model. Lessons learned from
WellNet study may inform other medical home models in Australian primary care settings.
Keywords: Patient-centred medical home; enhanced primary care; general practices; integrated care;
chronic care model
1. Introduction
The growing burden of non-communicable diseases including cardiovascular diseases (CVD),
diabetes, chronic obstructive pulmonary disease (COPD), mental illnesses, lung cancer, and
musculoskeletal disorders is a major cause of disability and death [1,2]. In Australia, chronic
diseases contributed towards 61% of the total disease (fatal and non-fatal) burden and 87% of all
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deaths in 2015 [3,4]. Furthermore, the burden of multiple chronic conditions (‘multimorbidity’) is a
major public health issue with recent findings reporting that the prevalence of Australians with two
or more and three or more conditions is 26% and 16%, respectively [5]. Studies show that patients
with multimorbidity often experience poor health-rated quality of life (HR-QOL) [6], psychological
distress [7], and increased mortality [8]. Multimorbidity is also associated with increased hospital
admissions [9], health care expenditure [10], and inappropriate polypharmacy [11]. Furthermore,
evidence suggests that the health burden of chronic diseases is projected to increase in the future,
thereby challenging health systems worldwide to revisit strategies towards effective management and
prevention [12,13].
Over the last few decades, advancements in public health policies and evidence-based medical
treatments have contributed to increased life expectancy [14]. Consequently, the higher life span has
resulted in a greater number of patients with comorbidities and, subsequently, a greater demand for
health services [15,16]. Health care systems in high-income countries, including Australia, are primarily
focused on the ‘single-disease framework’, where care delivery for the management of multimorbidity
is often fragmented, lacking integration and continuity of care [17]. Conversely, studies show that
coordinated and collaborative approaches in primary care with strong emphasis on self-management
of chronic diseases are effective in managing complex multimorbidity [18,19]. Therefore, the rising
demand for effective management of complex multimorbidity requires enhanced models of primary
care for better patient and health service delivery outcomes [20].
Primary health care is the cornerstone of Australia’s health care system, providing continual,
comprehensive and coordinated care that is targeted towards patients’ healthcare needs [21,22].
The country’s current primary health care system is built around a strong general practice foundation
and it is estimated that 85 percent of Australians consulted a GP at least once annually [3]. A number of
initiatives have recently been undertaken to integrate primary care for the management chronic diseases
by government and primary care organisations, including the ‘Australian Better Health Initiative’,
‘National Primary Health Care Strategy Framework’, and ‘Australian Primary Care Collaboratives
Program’ [23,24]. Though encouraging, primary care-based data and research on the effectiveness
and feasibility of these initiatives providing a coordinated, multi-disciplinary team (MDT) care for
long-term chronic disease management remains limited and not definitive [25,26].
The patient-centred medical home (PCMH) model has been lauded as providing the best model
of primary care for patients with one or more chronic diseases. This is due to provision of continuous,
comprehensive, and MDT care for collaborating services to meet patients’ health care needs [27].
Although definitions vary [28,29], the PCMH model typically includes a general practitioner (GP) as
part of a MDT, working in conjunction with patients to provide coordinated and focussed care that
promotes long-term patient engagement using a long-term chronic disease approach. There is a small
but growing body of evidence, primarily from the United States, suggesting that various models of
PCMH primary care are more effective than standard care in improving clinical outcomes in patients
with one or more chronic diseases [30,31], increasing the quality of care delivered [32,33] and reducing
hospital admissions [34,35]. However, in Australia, PCMH models have not been evaluated given the
country’s health care setting and funding models. Therefore, the aim of this article is to report on the
design, implementation, and early findings of the 12-month PCMH model called ‘WellNet’ delivered
across six primary care practices in Sydney, Australia. Additionally, this article will also detail the
overall aims and objectives of the WellNet study and the ongoing research activities conducted to
evaluate the study outcomes.
2. Materials and Methods
2.1. Design of the WellNet Chronic Disease Management (CDM) Program
Sonic Clinical Services (SCS) developed the 12-month WellNet chronic disease management
(‘WellNet’) program in 2016. This is closely aligned to the principles of the PCMH primary care model
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as it aims to deliver a coordinated and MDT model of care tailored directly to the needs of patients
according to the level of risk and complexity of their chronic conditions. This includes health coaching,
care navigation, education, self-management and regular review (Figure 1).
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Figure 1. Patient-centred medical home (PCMH) components used in the WellNet model.
The WellNet program combined face-to-face and telephone consultations with care coordinators
and GPs to provide optimal health outcomes through the delivery of patient-tailored healthcare
interventions. The interventions are based on the key pillars of:
• Patient identification and enrolment;
• Patient centr d integrated car ;
• Outcomes-based program philosophy;
• Data analytics, risk assessment and patient stratification;
• Evidence-based interventions;
• Shared electronic health records; and
• Patient education and teaching self-management skills.
The ell et progra structured interventions are based on the best available odels of care
applicable to the pri ary care setting. The progra is authored by ustralian and international
institutes, including the oyal ustralian ollege of eneral Practitioners ( P), iabetes
ustralia, ustralian Lung Foundation, Therapeutic Guidelines Expert Groups and the National Heart
Foundation [36–51]. As patients’ clinical presentations and needs are heterogeneous, the structured
interventions are adapted to meet an individual patient’s needs within the IT platform, cdmNET, and
with the guidance of the patients’ usual GP.
key co ponent of the progra is the involve ent of specialised chronic disease anage ent
( ) care coordinators at the edical centres. This as identified as key to successful integration
of a progra by the literature [52,53]. Supporting the care coordinators ere a ide range of
services and structured interventions. These included online and print educational materials directed at
encouraging behavioural change and a technology platform that facilitates the delivery of interventions
across a broad healthcare delivery team.
In a ition, patients ere provi e access to a user-frien ly application calle ‘ oShare’ hich
enables sharing of a range of health resources including video series, links to credible ebsites, apps,
an tools tailored to patients’ information needs. This program is aimed to improve self-efficacy,
self-management behaviours, and empower patients to play a more active role in their health care
ecisio s [54].
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The WellNet program consisted of 7 in-practice visits and 3 telephone contacts with the care
coordinator (2 contacts linked with GP appointments on commencement of the program) and quarterly
GP reviews (4 visits) making up to a total of 14 contacts. Flexibility with the number of contacts was also
provided according to patient’s needs and availability. Therefore, patients’ clinical and self-reported
outcomes were collected over 12 months plus or minus 3 months.
2.2. Specific and Broader Aims and Rationale of Study Design
This article aims to describe the design, implementation, and early findings of the 12-month
PCMH model called ‘WellNet’ delivered across six primary care practices in Sydney, Australia.
The broader aim of the WellNet study is to evaluate the effectiveness of a PCMH model for
improving clinical outcomes in primary care patients. The specific objectives of this study are to:
(1) evaluate changes in clinical outcomes in study participants compared to patients receiving standard
care between baseline and 12 months; (2) assess changes in participants’ self-reported health-related
quality of life (HR-QoL) and level of activation; (3) determine changes in the risk of hospital admissions;
(4) evaluate changes in disease-specific risk assessments; and (5) explore predictors of treatment uptake,
response, and compliance.
A cohort study design with a comparison group (aim (1)) and a case-series study design (aims (1)
to (5)) was used to evaluate WellNet’s ‘between group’ and ‘within group’ effectiveness. This was
for the WellNet program delivered in six general practices in Northern Sydney, New South Wales,
Australia. The rationale for using a synthetic comparison group was to have a sample that would be
similar to the WellNet treatment cohort at baseline, which in turn would be used to test the hypothesis
that WellNet group will have better clinical outcomes at 12 months compared to standard care.
2.3. Patient Characteristics
2.3.1. Treatment Group—Enrolment Methods and Outcome
The WellNet study’s treatment group constituted 636 patients from six primary care practices in
Northern Sydney who met the eligibility criteria to participate in the 12-month program and provided
written consent to have their data shared for evaluation.
The recruitment period for the study was between December 2016 and October 2017. SCS
developed and executed a computerised algorithm to identity from electronic medical records those
patients who met the diagnosis and risk factor criteria shown in Figure 2. The WellNet risk algorithm
categorised patients into four groups of complexity based on the number of chronic conditions and
presence of risk factors. Patients in groups C and D (the more complex cases) were the target groups
for the intervention, however eligibility was confirmed at initial assessment by Hospital Admission
Risk Profile (HARP) score.
Patients were eligible if they satisfied either criteria:
Criteria 1: Patients aged 40 years or above and who had seen a GP at least three times in the last
two years; had been diagnosed with one to three chronic diseases and had presented with one or more
elevated clinical risk factors; and held a HARP score of greater than 10 (medium risk or greater) OR
Criteria 2: Patients aged 40 years or above and who had seen a GP at least three times in the last
two years and had been diagnosed with four or more chronic diseases with or without one or more
risk factors; and held a HARP score of greater than 10 (medium risk or greater).
Additionally, patients with low HARP score (<10) but with at least one or more chronic diseases
and one or more consistently elevated risk factors were also included in the study through direct GP
referrals as GPs deemed them as good candidates that could benefit from the WellNet care.
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Figure 2. Eligibility criteria for the WellNet study. Dx–Diagnosis of chronic condition; BMI–Body Mass
Index; HbA1c–Glycated Haemoglobin; eGFR–estimated Glomerular Filtration Rate; UACR–Urine
Albumin Creatinine Ratio; LFT–Liver function test. ** Additionally, patients with low Hospital
Admission Risk Profile (HARP) score (<10) but with at least one or more chronic diseases and one or
more consistently elevated risk factors were also included in the study through general practitioner
(GP) referrals.
The care coordinators eliminated unsuitable patients, such as those living in nursing homes or
with significant cognitive impairment, before presenting a list of potentially eligible patients to GPs
for their review and selection. Potentially eligible patients were then contacted either through an
invitation letter (n = 1431) or by GP referrals during routine visits (n = 359). A minimum of three
follow-up phone calls were made by the care coordinator for each patient invited by letter who did not
respond directly to the letter.
Out of the total 1790 patients contacted, 698 (38.9%) attended the initial assessment. From the
initial assessment, 688 patients were found to be eligible for the program based on their HARP score.
Of these, 52 declined to participate in the WellNet Program or the cohort study, resulting in 636 (92.4%)
consenting eligible participants enrolled into the study.
2.3.2. Comparison Group—Matching Iterations and Outcomes
For matching purposes, four general practices with similar geographical proximity as WellNet
practices that did not provide PCMH care were chosen. In order to be concurrent with the enrolment
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period, patients who visited any one of the four general practices between December 2016 and October
2017 were identified (n = 20,478).
The Coarsened Exact Matching (CEM) was used to match treatment participants with the
comparison group. CEM is a Monotonoic Imbalance Bounding (MIB) matching method that temporarily
coarsens the data according to the researchers’ choice and then finds exact matches so that adjusting
the imbalance on one variable has no effect on the maximum imbalance of any other [55]. Using
‘Coarsened Exact Matching’ analysis in R, five different matching iterations were conducted. Several
variables including age (continuous and categorical), gender, chronic disease type (cardiovascular
disease, respiratory disease, diabetes, musculoskeletal disease, mental illness, and cancer), number of
chronic diseases, systolic blood pressure (continuous and categorical), and total cholesterol: HDL-C
ratio were considered to determine the best possible matching outcome, and from that, the best model
was chosen.
Subclass or strata groups without at least 1 treatment to 1 comparison patient were excluded.
CEM in turn returns ‘weights’ to compensate for differential strata sizes to be used in the subsequent
analyses [55]. This matching procedure has shown to effectively limit selection bias and variance
between the groups, thereby minimising bias in the final model showing treatment effects [55].
Table 1 provides the matching iteration numbers by the variables and their outcomes. Matching
iteration number 1 was chosen as the best model as it produced the highest number of matched patients
in both treatment and comparison groups whilst closely matching the two groups based on age and
gender, along with the same type and number of chronic diseases. Of the WellNet program group of
636 patients, 589 were matched to the comparison group (Figure 3).Int. J. Environ. Res. Public Health 2020, 17, x 8 of 22 
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Table 1. Matching iterations and outcomes.
Matching Iteration
Number Matching Variables
Treatment (Overall
n = 636)
Comparison (overall
n = 20478)
N (Matched Treatment:
Comparison)
N (Unmatched
Treatment: Comparison)
1
Age (continuous), gender, type of chronic
disease (cardiovascular disease, respiratory
disease, diabetes, musculoskeletal disease,
mental illness, and cancer) and number of
chronic diseases.
617 * 20478 * 589:7750 28:12728
2
Age (continuous), gender, type of chronic
disease (cardiovascular disease, respiratory
disease, diabetes, musculoskeletal disease,
mental illness, and cancer), systolic, and total
cholesterol: HDL-C ratio.
447 ** 3899 ** 228:604 219:3205
3
Age categories (breaks = 10 years), gender,
(cardiovascular disease, respiratory disease,
diabetes, musculoskeletal disease, mental
illness, and cancer), systolic, and total
cholesterol: HDL-C ratio.
447 ** 3899 ** 260:749 260:749
4
Age (continuous), gender, type of chronic
disease (cardiovascular disease, respiratory
disease, diabetes, musculoskeletal disease,
mental illness, and cancer), systolic (breaks =
2 mmHg), and total cholesterol:
HDL-C ratio.
447 ** 3899 ** 202:517 245:3292
5
Age categories (breaks = 10 years), gender,
(cardiovascular disease, respiratory disease,
diabetes, musculoskeletal disease, mental
illness, and cancer), systolic (breaks =
2 mmHg), and total cholesterol:
HDL-C ratio.
447 ** 3899 ** 242:735 205:3074
HDL-C–High Density Lipoprotein Cholesterol; * Of the 636 WellNet participants, 19 did not have a chronic disease and were not included in the matching analysis, resulting in 617
participants; ** Out of 636 WellNet participants, 19 did not have a chronic disease, 15 did not have a systolic reading and 166 did not have a TC: HDL reading, and they were automatically
removed during matching. Similarly, out of 20478 comparison patients, 9176 did not have a chronic disease, 3169 did not have a systolic reading and 4234 did not have a TC: HDL reading,
and they were automatically removed during matching.
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2.4. Provider Characteristics
A total of 66 GPs were invited to participate in a Likert scale survey on their perspectives on
(1) chronic disease management; (2) WellNet program; and (3) PCMH model of care. In addition, some
sociodemographic characteristics on age, gender, place of graduation and years of general practice
experience were also collected.
2.5. Follow-Up
There are two phases of follow-up in the WellNet program. Phase 1 involved follow-up at 12 months
to evaluate changes in clinical outcomes, HARP, Patient Activation Measure (PAM), self-reported
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L), and other disease-specific risk assessments [49,56–65].
Phase 2 of the evaluation is planned as a two-year post intervention follow-up that will study
changes in health services utilisation and medication prescription with the use of hospital-linked
administrative datasets.
2.6. Data Collection
Data collected at various stages of baseline and follow-up from participants included
sociodemographic information, private health insurance membership status, lifestyle risk factors,
chronic disease diagnoses, clinical measures (as clinically relevant), and several validated health-related
surveys that participants were asked to complete upon enrolment (Table 2). These surveys involved
information regarding:
(a) health-related quality of life,
(b) level of health engagement and activation,
(c) self-management of their health,
(d) other disease-specific risk assessments.
Table 2. Summary of data collected in the WellNet Study.
Type of Data Time of Data Collection Variables Measured
Socio-demographic data Baseline Age and gender
Private health insurance membership Baseline Private insurance status and name of theinsurance provider
Diagnosis of chronic condition Baseline
Diagnosis of arthritis, asthma, back pain, cancer,
cardiovascular diseases (CVD), chronic obstructive
pulmonary disease (COPD), diabetes, mental illness
and kidney diseases.
Clinical assessments
Baseline
6-month
12-month
Height, weight, waist circumference, Body Mass
Index (BMI), blood pressure (BP), blood sample -
cholesterol [serum total cholesterol, high density
lipoprotein cholesterol (HDL-C) and low-density
lipoprotein cholesterol (LDL-C)], triglycerides,
glycated haemoglobin (HbA1c), estimated glomerular
filtration rate (eGFR), and urine albumin-creatinine
ratio (UACR).
Risk of hospital admission Baseline12-month
Hospital Admission Risk Profile (HARP) score to
estimate the risk of hospitalisation in the next
12 months
Health utility data Baseline12-month
Medication–drug name, dosage and frequency of use
and number of prescriptions.
Patient activation, engagement and
readiness to change
Baseline
12-month
Patient Activation Measure (PAM) scores to evaluate
patient self-efficacy and self-management behaviours
Patient self-reported health-related
quality of life
Baseline
12-month
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) to assess
patient’s heath related quality of life
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Table 2. Cont.
Type of Data Time of Data Collection Variables Measured
Disease-specific risk assessments Baseline12-month
Absolute Cardiovascular Disease Risk (CVDR),
Australian Type 2 Diabetes Risk Tool (AusDrisk)
scores, UK Prospective Diabetes Risk Engine
(UKPDS), Chronic Obstructive Pulmonary Disease
Assessment Test (CAT) scores, Kessler Psychological
Distress scale (K10) scale, Depression Anxiety Stress
Scale (DASS21), short versions of Knee Injury and
Osteoarthritis Outcome Score (KOOS), Hip Disability
and Osteoarthritis Outcome Score (HOOS).
Patient experience survey 12-month
Patient satisfaction survey on quality of care
outcomes; patient-provider relationship,
communication, and empowerment outcomes; and
access to information technology outcomes.
Feasibility outcomes 12-month
Recruitment: number of patients’ who potentially
met the program’s inclusion criteria;
Retention rates: number of completed and dropouts;
Treatment compliance: rates of adherence to
overall protocol.
2.7. Statistical Analyses
Data extraction on the WellNet program group and the comparison group were provided by SCS
to the researchers. The data were provided in de-identified form and the patient’s cdmNET number
was used to track patients over time.
2.7.1. Analysis Conducted to Date
Descriptive statistics are presented as mean and standard deviation (SD) for continuous variables
whereas frequency counts and percentages are used for reporting categorical variables. Independent
samples t-test was conducted to determine significant differences between treatment and comparison
group at baseline.
2.7.2. Ongoing Analysis
To assess changes over time between baseline and 12 months, significant within-group mean
differences (pre-test/post-test) from baseline to 12 months will be determined by using Paired samples
t-test. In addition, between-group analyses (treatment and comparison group) will be conducted to
determine significant mean differences using independent samples t-tests and chi-squared tests for
continuous and categorical variables, respectively. Furthermore, analysis of covariance (ANCOVA)
and repeated measures ANCOVA will be used to determine any significant between-group and
within-group differences in the clinical measures and assessments after adjusting for covariates such as
age, gender and baseline values. Finally, multivariate regression analyses using the backward stepwise
method will be used to determine predictors of several clinical endpoints at 12-month follow-up.
All analyses will be performed using R statistical software. Significance level is set as 0.05 and all
statistical tests will be two-sided.
2.8. Ethical Considerations
The study was reviewed by the Western Sydney University Human Research Ethics Committee
(REDI Reference: H12215). Written informed consent was obtained from the study participants.
3. Results and Discussion
Since the WellNet study is ongoing, the baseline findings on recruitment outcomes, baseline
clinical and health assessment surveys along with provider level experiences at baseline are described.
We have also discussed the strengths and limitations of the WellNet study along with potential
determinants affecting study reproducibility.
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3.1. Recruitment Outcomes
Almost 98% of the patients enrolled in the WellNet program were over 40 years of age and
with 93% having one to three chronic conditions with one or more risk factors present, and 98% of
participants had a HARP score in the >10 range (medium or greater risk). Thereby, it can be observed
that the patient identification algorithm used was effective in identifying those patients who potentially
met the program’s inclusion criteria (Table 3).
Table 3. Feasibility outcomes.
Criteria Success Rate
Age
40 years and above 97.5%
Number of chronic diseases
Number of patients with 1 to 3 chronic diseases 93.4%
Number of patients with 4 or more chronic diseases 6.6%
Risk factors
Patients with 1 chronic disease (n = 227)
1 risk factor 47.6%
>1 risk factor 31.7%
Patients with 2 chronic diseases (n = 237)
1 risk factor 42.6%
>1 risk factor 27.4%
Patients with 3 chronic diseases (n = 115)
1 risk factor 40%
>1 risk factor 35.7%
Patients with 4 or more chronic diseases (n = 38)
1 risk factor 44.7%
>1 risk factor 26.3%
HARP score >10 97.7%
3.2. Sociodemographic Characteristics
The key demographic findings are presented in Table 4. The mean (SD) age of the study participants
was 70.05 (11.6) years with nearly even gender distribution of males (49.7%) and females (50.3%).
A majority of participants (68.7%) in the WellNet treatment group had private health insurance. There
is higher than usual patients with private health insurance (PHI) because of higher socioeconomic
status of North Sydney region and the PHI members targeted for intervention.
Table 4. Sociodemographic characteristics and prevalence of chronic conditions in the treatment and
comparison group.
Determinants
WellNet Treatment
Group (N = 589)
WellNet Comparison
Group (N = 7750) p-Value
N (%) N (%)
Age groups 0.798
40–44 years 7 (1.2) 141 (1.8)
45–54 years 57 (9.7) 722 (9.3)
55–64 years 118 (20.0) 1580 (20.4)
65–74 years 188 (31.9) 2360 (30.4)
75–84 years 156 (26.5) 2029 (26.2)
≥85 years 63 (10.7) 918 (11.8)
Mean (SD) 70.05 (11.59) 69.95 (11.86)
Sex 0.936
Male 293 (49.7) 3842 (49.6)
Female 296 (50.3) 3908 (50.4)
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Table 4. Cont.
Determinants
WellNet Treatment
Group (N = 589)
WellNet Comparison
Group (N = 7750) p-Value
N (%) N (%)
Smoking status
Ex–smoker 237 (42.1) 2274 (36.4) <0.001
Non–smoker 280 (49.7) 3655 (58.6)
Smoker 46 (8.2) 309 (5.0)
Unknown 26 (4.4) 1512 (19.5)
Drinking status
Drinker 256 (43.5) 1465 (18.9) <0.001
Non–drinker 176 (29.9) 147 (1.9)
Unknown 156 (26.5) 6138 (79.2)
Private insurance status
Yes 404 (68.7)
NA
–
No 184 (31.3)
Missing 1 (0.2)
Prevalence of chronic conditions 1.000
Diseases of the circulatory system 411 (69.8) 5408 (69.8)
Respiratory diseases 169 (28.7) 2224 (28.7)
Musculoskeletal disorders 256 (43.5) 3368 (43.5)
Diabetes 279 (47.4) 3671 (47.4)
Mental illness 111 (18.8) 1461 (18.8)
Cancer 80 (13.6) 1053 (13.6)
Number of chronic conditions 1.000
1 disease 133 (22.6) 1750 (22.6)
2 diseases 249 (42.3) 3276 (42.3)
3 diseases 159 (27.0) 2092 (27.0)
4 diseases 42 (7.1) 553 (7.1)
≥5 diseases 6 (1.0) 79 (1.0)
SD-Standard Deviation; NA—not available.
3.3. Chronic Disease Diagnosis and Clinical Indicators
The prevalence of chronic disease among the treatment and comparison group was similar.
The most prevalent chronic diseases in descending order were: circulatory system disorders (69.8%),
diabetes (47.4%), musculoskeletal disorders (43.5%), respiratory diseases (28.7%), mental illness (18.8%),
and cancer (13.6%). Consistent with other Australian studies [66,67], the distribution of chronic diseases
significantly differed across age groups as the number of chronic diseases generally increased with age
(Figure 4). In terms of gender distribution, diabetes (54.8%) was significantly more prevalent amongst
males than females (40.1%), whilst considerably more females had musculoskeletal disorders (54.3%
vs. 31.3%), respiratory (34.1% vs. 23.8%), and mental illness (23.7% vs. 16.9%) than males.
Descriptive statistics of clinical measures for the treatment and comparison group are present
in Table 5. Although treatment and comparison groups were effectively matched based on the type
and number of chronic conditions, findings of the independent t-tests show significant differences in
blood pressure, glycated haemoglobin (HbA1c), Low Density Lipoprotein Cholesterol (LDL-C), total
cholesterol, and waist circumference (females only) between the treatment and comparison group.
However, there were no statistically significant differences between treatment and comparison group
for clinical measures like Body Mass Index (BMI), weight, waist circumference (males only), High
Density Lipoprotein Cholesterol (HDL-C), estimated Glomerular Filtration Rate (e-GFR), and Albumin
Creatinine Ratio (ACR) at baseline. In order to effectively manage baseline differences, ANCOVA will
be used to determine any significant between-group differences in the clinical measures after adjusting
for covariates such as age, gender and baseline values.
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Figure 4. Distribution of chronic disease prevalenc by age groups among WellNet pati nts. Chi- quared
test betwe n age group and n mber of chronic condit ons returned a p < 0.001.
Table 5. Clinical measures among treatment and comparison group collected at baseline.
Clinical Measures
WellNet Treatm nt
Group (N = 589)
WellNet C mparison
Group (N = 7750) p-Value
N (%) N (%)
Systolic blood pressure (mmHg),
Mean (SD) 139.37 (19.30) 135.96 (16.51) <0.001
Dia tolic blo d pressure (mmHg),
Mean (SD) 79.27 (10.32) 76.02 (11.31) <0.001
Body Mass Index, Mean (SD) 29.54 (6.36) 29.12 (5.63) 0.151
Weight (kg)–Mean (SD) 81.81 (20.72) 81.73 (19.70) 0.930
Waist Circumference* (Males)
(cm), Mean (SD) 106.09 (15.63) 104.30 (14.30) 0.120
Waist Circumference* (Females)
(cm), Mean (SD) 98.82 (14.62) 93.15 (12.47) <0.001
HbA1c (%), Mean (SD) 7.16 (1.41) 6.71 (1.24) <0.001
HDL-C (mmol/L), Mean (SD) 1.37 (0.40) 1.40 (0.42) 0.147
LDL-C (mmol/L), Mean (SD) 2.71 (1.08) 2.52 (0.98) <0.001
Serum total cholesterol (mmol/L),
Mean (SD) 4.81 (1.38) 4.60 (1.13) <0.001
Estimated Glomerular Filtration
Rate (mL/min/1.73m2)
>90 mL/min/1.73 m2 109 (24.9) 1467 (24.8) 0.868
60–89 mL/min/1.73 m2 247 (56.5) 3436 (58.2)
45–59 mL/min/1.73 m2 46 (10.5) 622 (10.5)
30–44 mL/min/1.73 m2 26 (5.9) 274 (4.6)
<30 mL/min/1.73 m2 9 (2.0) 106 (1.8)
Missing 152 (25.8) 1845 (23.8)
Albumin-Creatinine Ratio*
(mg/mmol) (Males), Mean (SD) 15.52 (67.54) 13.08 (53.18) 0.653
Albumin-Creatinine Ratio*
(mg/mmol) (Females), Mean (SD) 7.53 (22.31) 8.07 (32.12) 0.878
SD - Standard deviation; HbA1c–Glycated Haemoglobin; HDL-C - High Density Lipoprotein Cholesterol; LDL-C
- Low Density Lipoprotein Cholesterol; p-value by Chi-square test (categorical) or independent samples t-test
(continuous) between treatment and control group; *Variables with gender-specific cut-off points.
Int. J. Environ. Res. Public Health 2020, 17, 2164 13 of 21
3.4. Self-Reported Health Assessments
General health and disease-specific risk assessments were recorded only among the WellNet
treatment group (Table 6). As targeted, around 98% of participants had medium risk or greater HARP
scores. The majority of study participants self-rated their health positively with mean EQ-5D-5L index
score of 0.79 out of 1. Consistent with other studies [68,69], the mean EQ-5D-5L score significantly
decreased with increased number of chronic diseases (p < 0.001). In terms of patient activation and
self-management, only 21% reported having actively changed their health-related behaviour, with 22%
beginning to take actions at baseline. However, 19% believed that action was not important, with a
majority of participants (38%) reporting that the biggest difficulty in attempting to change behaviour
was a lack of confidence or knowledge in managing and improving their condition.
Table 6. General and disease-specific assessments among WellNet treatment group only at baseline.
Patient Survey Questionnaires WellNet Treatment Group (N = 635)
n (%)
Hospital Admission risk profile (N = 628)
Low risk (1–10) 14 (2.2)
Medium risk (11–23) 581 (92.5)
High risk (24–38) 33 (5.3)
Missing 7 (1.1)
Patient Activation Measure scores (N = 626)
Not believing that activation is important (<47) 121 (19.3)
A lack of knowledge and confidence to take action
(47.1–55.1) 236 (37.7)
Beginning to take action (55.2–67) 138 (22.0)
Taking action (>67.1) 131 (20.9)
Missing 9 (1.4)
Mean EQ-5D-5L score (overall)–Mean (SD) 0.79 (0.19)
EQ-5D-5L score percentage
EQ-5D-5L mobility (N = 626)
No problem 298 (47.6)
Slight problem 171 (27.3)
Moderate problem 108 (17.3)
Severe problem 47 (7.5)
Unable to walk 2 (0.3)
Missing 9 (1.4)
EQ-5D-5L self-care (N = 623)
No problem 521 (83.6)
Slight problem 79 (12.7)
Moderate problem 19 (3.0)
Severe problem 4 (0.6)
Unable 0 (0.0)
Missing 12 (1.9)
EQ-5D-5L usual activities (N = 626)
No problem 312 (49.8)
Slight problem 187 (29.9)
Moderate problem 98 (15.7)
Severe problem 26 (4.2)
Unable 3 (0.5)
Missing 9 (1.4)
EQ-5D-5L pain/discomfort (N = 627)
No problem 156 (24.9)
Slight problem 246 (39.2)
Moderate problem 165 (26.3)
Severe problem 55 (8.8)
Extreme 5 (0.8)
Missing 8 (1.3)
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Table 6. Cont.
Patient Survey Questionnaires WellNet Treatment Group (N = 635)
n (%)
EQ-5D-5L anxiety/depression (N = 629)
No problem 321 (51.0)
Slight problem 190 (30.2)
Moderate problem 94 (14.9)
Severe problem 16 (2.5)
Extreme 8 (1.3)
Missing 6 (0.9)
DASS21 Scores (N = 331)
DASS21–Depression scale
Normal 230 (69.5)
Mild 26 (7.9)
Moderate 40 (12.1)
Severe 12 (3.6)
Extremely severe 23 (6.9)
DASS21–Anxiety scale
Normal 211 (63.7)
Mild 32 (9.7)
Moderate 53 (16.0)
Severe 14 (4.2)
Extremely severe 21 (6.3)
DASS21–Stress scale
Normal 260 (78.5)
Mild 29 (8.8)
Moderate 20 (6.0)
Severe 15 (4.5)
Extremely severe 7 (2.1)
K10 scores (N = 302)
Low level of psychological distress 137 (45.4)
Moderate level of psychological distress 88 (29.1)
High level of psychological distress 49 (16.2)
Very high level of psychological distress 28 (9.3)
UKPDS risk profile (N = 140)
Coronary Heart Disease risk - mean percentage (SD) 18.98 (14.11)
Fatal Coronary Heart Disease risk - mean percentage
(SD) 14.94 (16.14)
Stroke risk - mean percentage (SD) 14.37 (15.10)
Fatal stroke risk - mean percentage (SD) 2.33 (2.60)
Missing 53 (27.5)
AusDRisk scores (N = 220)
Low risk 5 (2.3)
Intermediate risk 34 (15.5)
High risk 181 (82.3)
Missing 137 (38.4)
Absolute cardiovascular risk (N = 370)
Low risk 167 (45.1)
Moderate risk 84 (22.7)
High risk 119 (32.2)
Missing 48 (11.5)
COPD impact scores (N = 26)
Normal 2 (7.7)
Low 4 (15.4)
Medium 12 (46.2)
High 3 (11.5)
Very high 5 (19.2)
Missing 38 (59.4)
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Table 6. Cont.
Patient Survey Questionnaires WellNet Treatment Group (N = 635)
n (%)
HOOS score (N = 31)
HOOS pain score - Mean (SD) 64.92 (23.37)
HOOS function score - Mean (SD) 68.95 (19.80)
HOOS symptoms score - Mean (SD) 66.15 (17.23)
Missing 168 (84.4)
KOOS score (N = 59)
KOOS stiffness score - Mean (SD) 61.86 (28.37)
KOOS pain score - Mean (SD) 64.72 (22.01)
KOOS function score - Mean (SD) 63.13 (25.58)
KOOS symptoms score - Mean (SD) 63.09 (18.14)
Missing 140 (70.3)
SD—Standard Deviation; EQ-5D-5L—Euro-Qol Five dimensions and Five levels; DASS21—Depression Anxiety
Stress Scale 21 questions version; K10—Kessler’s Psychological Distress scale; AusDRisk—Australian Type-2
Diabetes Risk score; COPD—Chronic Obstructive Pulmonary Disease; HOOS—Hip Disability and Osteoarthritis
Outcome Score; KOOS—Knee Injury and Osteoarthritis Outcome Score.
3.5. Provider-Level Findings
3.5.1. Provider-Level Baseline Characteristics
Of 66 eligible GPs, 49 (74%) responded to the self-reported survey. 62.5% of GPs were aged 55
and above and almost two-thirds (63.3%) had graduated in Australia. More than 63% reported more
than 20 years of experience working in general practice.
3.5.2. GPs Perspectives on Chronic Disease Management
At baseline, GPs were largely of the opinion (67% strongly agreed or agreed) that they had
systematic approaches toward patients with chronic disease. Likewise, 70% of GPs reported using
the skills and support of their practice nurses and primary care team. Around 90% stated that they
routinely prepared chronic disease management plans for their patients and liaised with patients’ care
teams. However, only 50% reported regularly reviewing and updating their disease management
plans. How the latter number changes over the course of the twelve months of Phase 1 is of especial
interest to the program.
3.5.3. GPs Perspectives on WellNet Study
On the whole, GPs held positive perspectives toward the WellNet program. The majority of
clinicians (>70%) agreed or strongly agreed that they were familiar with the concept of the program.
GPs also reported to have excellent relationships with their primary care team (85% agreed or strongly
agreed) as well as had confidence that clinical teams were providing highly coordinated care (77%).
Thirty-seven GPs identified and referred patients to the WellNet program and were confident that
patients would benefit from the program. However, eleven stated that they had not. Of these, the most
common reason was that the doctors in question did not know how to identify and refer patients to the
program (n = 5). If these numbers have not changed after twelve months, greater clinician engagement
may be necessary. One clinician stated that they did not believe the program had benefits to their
patients, whilst one GP each stated that they had not identified any patients yet, had just started the
program, or did not have any eligible patients.
3.5.4. GPs Perspectives on PCMH Model
On the whole, it seems that clinicians were relatively aware of the PCMH concept (61% strongly
agreed or agreed). These numbers should be expected to improve over twelve months. The majority of
GPs were also optimistic that voluntary patient enrolment can enhance patient care (79%) and that
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they involved clinicians in the design of health service delivery (83%), while most also believed that
they worked collaboratively in their practices and that clearly defined roles and responsibilities existed
amongst staff.
It should also be noted that clinicians strongly valued patient feedback: nearly 40% strongly
agreed, while 55% agreed. That said, only 71% agreed or strongly agreed that they had sufficient
data for evaluating and improving their practices, and 81% believed that they were encouraged or
supported to improve care quality and safety—indicating that there may be gaps in the collection or
utilisation of patient outcome and experience data or insufficient structures in place that could support
quality improvement.
3.6. Factors Affecting Reproducibility of Study Findings
Similar to other studies based on an originally developed program, reproducibility of study
findings is constrained by the uniqueness of the data and also by several patient and provider-level
determinants. Patients’ levels of education, social gradient, and health behaviour and practices would
have different levels of impact towards improved health coaching and self-management practices
leading subsequently to varying levels of management. For instance, patients with a higher level
of education will better perceive the importance of self-management and would be more likely
to adhere to health coaching provided by the GPs and care coordinators in the WellNet program.
In terms of provider-level determinants, varying levels of experience and training among GPs and care
coordinators will impact quality of care in terms of effectively delivering PCMH care.
3.7. Study Strengths
Despite general practices being the first point of health-related interactions among the predominant
percentage of Australians, research based on GP data is disproportionately low [25]. To our knowledge,
the WellNet program is the first study in Australia to generate the first real-world evidence on the
feasibility and effectiveness of a comprehensive PCMH model with the use of primary care-based data.
The study comprises a large, effectively targeted sample with wide range of GP-based data on chronic
disease diagnosis as well as self-reported risk assessments. The use of general and disease-specific
self-reported health assessments recorded among study participants helps understand patients’ quality
of life, self-management practices, and severity of diseases in addition to routine clinical metrics.
Furthermore, use of validated questionnaires renders better quality of data with improved credibility
as well as higher comparability with other sample populations. In addition, the study also includes
standardised clinical measurements that are collected by trained health care professionals as opposed
to self-reported information, thereby eliminating any potential self-reporting bias.
3.8. Study Limitations
The WellNet program has some limitations in terms of the evaluation study design and data.
The WellNet study was based on the case series study design for the treatment group only and did
not include a control group. Therefore, analyses of self-reported assessments were limited to ‘within
group’ comparisons rather than ‘between groups’. Although the treatment group was closely matched
with the comparison group based on age, gender, type and number of chronic diseases, there were
statistically significant differences observed across some clinical measures between the two groups
at baseline. To minimize this, ANCOVA techniques will be used to control for baseline differences.
In terms of data limitations, the reason why 52 patients declined from participation was not recorded.
The impact of each component of PCMH contributing to primary and secondary outcomes was not
explored. In addition, facilitators or barriers that contributed to early implementation experiences
were also not recorded.
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4. Conclusions
There has been increased advocacy to implement PCMH models for effective management at the
primary care level worldwide. The WellNet study is one of the few studies in Australia to generate
evidence on the feasibility of design, recruitment, and implementation of a comprehensive PCMH
model. To date, the recruitment outcomes of WellNet study indicate that the patient algorithm was
effective in identifying eligible patients for enrolment.
Lessons learnt from the baseline findings include understanding of the characteristics of the
sample participants not only in terms of their chronic disease diagnosis, but also to assess their level
of self-management behaviours, quality of life and other disease-specific surveys at baseline. As the
PCMH model aims to provide a structured patient-tailored chronic disease management with focus
on self-management behaviours, the baseline lifestyle and other health behaviours of the sample
participants recorded at the start of the program enables GPs to better understand individual needs
and provide better quality of care.
However, upon completion, we expect that the findings of WellNet study will inform patients on
the benefits of the PCMH model in terms of improved clinical outcomes and quality of care, as well as
reduced risk of hospitalisation.
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